Collins Helen Louise

CHIEF MEDICAL OFFICER

Collins Helen Louise has filed 10 SEC Form 4 filings (32 transaction rows) across 1 company, with disclosures dating back to 2026. 10 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.

On the most recent filing, Collins Helen Louise is listed as CHIEF MEDICAL OFFICER at Enliven Therapeutics, Inc. Inside the rolling window, Collins Helen Louise reported no open-market purchases and 10 open-market sales totaling $5.1M in ELVN. The largest disclosed transaction in the window is a sale of 40,000 ELVN shares on Mar 25, 2026, worth $1.4M.

Companies traded

Other insiders at ELVN

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$5.1M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ELVNSale$293KAug 19SEC ↗
ELVNSale$263KJul 21SEC ↗
ELVNSale$219KJun 22SEC ↗
ELVNSale$199KMay 20SEC ↗
ELVNSale$238KApr 21SEC ↗
ELVNSale$1.4MMar 27SEC ↗
ELVNSale$139KMar 19SEC ↗
ELVNSale$897KMar 11SEC ↗
ELVNSale$306KMar 11SEC ↗
ELVNSale$1.2MFeb 19SEC ↗

Frequently asked questions

How many SEC Form 4 filings has Collins Helen Louise made?

Collins Helen Louise has filed 10 SEC Form 4 filings (32 transaction rows) across 1 company since 2026.

Which companies does Collins Helen Louise trade?

Collins Helen Louise has filed SEC Form 4 disclosures for 1 company, including ELVN.

When was Collins Helen Louise's most recent SEC Form 4 filing?

Collins Helen Louise's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.

What is Collins Helen Louise's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Collins Helen Louise is listed as CHIEF MEDICAL OFFICER.

What is Collins Helen Louise's total buy and sell value in the current window?

Inside the rolling retention window, Collins Helen Louise bought $0 and sold $5.1M based on SEC Form 4 filings.

What was Collins Helen Louise's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 40,000 ELVN shares on 2026-03-25, worth $1.4M, per SEC Form 4 filings.